← All trials
NCT06901505
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 24, 2025
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2026
- First posted
- Mar 30, 2025
- Last posted
- Sep 25, 2025
- Enrollment
- 350
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Akebia TherapeuticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.